Fuse Medical Announces Exclusive US Distribution Agreement with BRM Extremities for Silktoe Arthroplasty Implant
Silktoe® offers patients with severe arthritis in the metatarsophalangeal joint another option outside of fusion. The design is derived from historical silastic toe arthroplasty devices and evolved to offer a more anatomical fit and replication of natural anatomical motion.
The system consists of an elastomeric silicone spacer placed within each of the two bones comprising the metatarsophalangeal joint during toe arthroplasty and secured in place by titanium grommets. Available in five different sizes specific to the left or right foot, Silktoe® is sterile packaged and ready for implantation.
Silktoe® is intended for arthroplasty of the first metatarsophalangeal joint (MTP1) of the foot. It represents a permanent implant, used in all severe forms of arthritis, such as: hallux rigidus or hallux limitus, painful rheumatoid arthritis, hallux abducto valgus associated with arthritis, or unstable or painful joint from previous surgery.
“Adding Silktoe® to our lower extremity portfolio aligns with Fuse’s focus on delivering products based on replication of anatomical motion,” commented
Reeg further added, “We are committed to adding both proven and innovative devices to our comprehensive portfolio of products within the spine, total joint, extremity, sports medicine, and biologics divisions. New technologies like Silktoe®, demonstrate our priority at Fuse remains to provide effective solutions for today’s clinical challenges and assist with improving surgical outcomes.”
About
Fuse is an emerging manufacturer and distributor of innovative medical devices for the orthopedic and spine marketplace. We provide a comprehensive portfolio of products in the orthopedic total joints, sports medicine, trauma, foot and ankle space, as well as, degenerative and deformity spine, osteobiologics, wound care, and regenerative products. For more information about the Company, or if you’re interested in becoming a distributor of any Fuse’s products, please contact us at info@fusemedical.com or visit: www.fusemedical.com.
Forward Looking Statements
Certain statements in this press release, constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend,” or similar expressions or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based only on information available to the Company as of the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including, without limitation, those set forth in the Company’s filings with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20211215005291/en/
Office (469) 862-3030
Facsimile (469) 862-3035
info@Fusemedical.com
Source: